Tissue Engineering Stem Cells – An e-Governance Strategy

Simon Grange*
Alberta Bone and Joint Health Institute, McCaig Institute, University of Calgary, Canada

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 933
Abstract HTML Views: 458
PDF Downloads: 619
Total Views/Downloads: 2010
Unique Statistics:

Full-Text HTML Views: 575
Abstract HTML Views: 269
PDF Downloads: 256
Total Views/Downloads: 1100

Creative Commons License
© Simon Grange; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Alberta Bone and Joint Health Institute, McCaig Institute, University of Calgary, Canada; Tel: 001 (403) 702-6402; Fax: 001 (403) 283-1778; E-mail:


The rules of governance are changing. They are necessarily becoming more stringent as interventions offered to treat conditions carry unpredictable side effects, often associated with novel therapeutic vectors. The clinical relevance of this relates to the obligations of those involved in research, to ensure the best protection for subjects whilst encouraging the development of the field. Existing evidence supports the concept of e-Governance both in operational health research and more broadly in the strategic domain of policy formation. Building on the impact of the UK Comprehensive Research Network and recent EU Directives, it is now possible to focus on the issues of regulation for cell therapies in musculoskeletal science through the development of the Advanced Therapeutic Medicinal Products (ATMP) category of research products. This article reviews the framework that has borne this and the need for more detailed Virtual Research Integration and Collaboration (VRIC) systems to ensure regulatory compliance. Technology research and development plans must develop in close association between tissue engineering and treating clinicians. The scope of this strategy relates to the handling of human tissues the transport and storage of specimens in accordance with current EU directives and the Human Tissue Authority (HTA) regulations.

Keywords: Cell therapies, governance, intervention, regulations, research, tissue engineering.